Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 5866 AL 5880

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A.

Lancet Neurol. 2012 Jul;11(7):597-604. doi: 10.1016/S1474-4422(12)70140-0. Epub 2012 Jun 6.

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease

Tariot P, Salloway S, Yardley J, Mackell J, Moline M.

BMC Res Notes. 2012 Jun 8;5:283. doi: 10.1186/1756-0500-5-283.

Gene transfer to skeletal muscle by site-specific delivery of electroporation and ultrasound

Li Y, Wang J, Satterle A, Wu Q, Wang J, Liu F.

Biochem Biophys Res Commun. 2012 Jul 27;424(2):203-7. doi: 10.1016/j.bbrc.2012.06.090. Epub 2012 Jun 26.

Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease?

Brown BM, Peiffer JJ, Martins RN.

Mol Psychiatry. 2013 Aug;18(8):864-74. doi: 10.1038/mp.2012.162. Epub 2012 Nov 20.

Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?

Mullane K, Williams M.

Biochem Pharmacol. 2013 Feb 1;85(3):289-305. doi: 10.1016/j.bcp.2012.11.014. Epub 2012 Nov 23.

Research and standardization in Alzheimer's trials: reaching international consensus

Carrillo MC, Rowe CC, Szoeke C, Masters CL, Ames D, O'Meara T, Macaulay SL, Milner A, Ellis KA, Maruff P, Rainey-Smith SR, Martins RN, Bain LJ, Head RJ; NIA/Alzheimer Association and International Working Group.

Alzheimers Dement. 2013 Mar;9(2):160-8. doi: 10.1016/j.jalz.2012.10.006. Epub 2012 Dec 23.

Cellular and molecular actions of Methylene Blue in the nervous system

Oz M, Lorke DE, Hasan M, Petroianu GA.

Med Res Rev. 2011 Jan;31(1):93-117. doi: 10.1002/med.20177.

Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease

Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T.

Neurobiol Aging. 2011 Sep;32(9):1626-33. doi: 10.1016/j.neurobiolaging.2009.10.009. Epub 2009 Nov 17.

TGF-β1 pathway as a new target for neuroprotection in Alzheimer's disease

Caraci F, Battaglia G, Bruno V, Bosco P, Carbonaro V, Giuffrida ML, Drago F, Sortino MA, Nicoletti F, Copani A.

CNS Neurosci Ther. 2011 Aug;17(4):237-49. doi: 10.1111/j.1755-5949.2009.00115.x. Epub 2009 Nov 19.

Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin

Alvarez XA, Cacabelos R, Sampedro C, Aleixandre M, Linares C, Granizo E, Doppler E, Moessler H.

Eur J Neurol. 2011 Jan;18(1):59-68. doi: 10.1111/j.1468-1331.2010.03092.x.

Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment

Wattmo C, Wallin ÅK, Londos E, Minthon L.

Alzheimer Dis Assoc Disord. 2011 Jan-Mar;25(1):63-72. doi: 10.1097/WAD.0b013e3181f5dd97.

Non-cholinergic pharmacotherapy approaches to Alzheimer's disease: the use of non-steroidal anti-inflammatory drugs

Tsartsalis S, Panagopoulos PK, Mironidou-Tzouveleki M.

CNS Neurol Disord Drug Targets. 2011 Feb;10(1):133-9. doi: 10.2174/187152711794488629.

Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease

Lee JH, Sevigny J.

Alzheimer Dis Assoc Disord. 2011 Jan-Mar;25(1):58-62. doi: 10.1097/WAD.0b013e3181f32829.

Recent developments in tau-based therapeutics for neurodegenerative diseases

Medina M.

Recent Pat CNS Drug Discov. 2011 Jan;6(1):20-30. doi: 10.2174/157488911794079091.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias